Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with participation from GV and existing investor Alphabet, Google’s parent, it said. The funding will accelerate further development of Isomorphic’s AI drug […]
Source : Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive
